Histopathological Analysis and Correlation of Ki67 and Progesterone Receptor Status with WHO Grading In Meningiomas
Keywords:
Meningioma, progesterone receptor, immunohistochemistry, prognosis.
Abstract
Background: Meningiomas are slow growing tumors that are among the most common of CNS neoplasms and form the most common CNS tumor to be reported above 35 years of age. Materials & Methods: This retrospective study was carried out in the Department of Pathology during the period of January2011 to May2013. A total of 50 cases were graded according to the WHO 2016 grading criteria. The biopsy specimens were fixed in 10% neutral buffered formalin, sections was stained with Hematoxylin & Eosin. Immunohistochemistry was done with Progesterone receptor and Ki67 antibodies for selected cases. Results: The incidence of meningiomas was 33.11% with a female sex predilection and most common in the 5th decade. Transitional meningioma was the most common variant to occur. The incidence of WHO Grade I, Grade II and Grade III meningiomas were 88%, 4% and 8% respectively. Comparison of Ki67 LI and PR score in various grades of meningiomas were done. The average Ki67 LI and PR score were 1.1%, 10.25; 6%, 3; 16%, 0 in grade I, II and III meningiomas respectively. p value showed a statistically significant difference between different grades of meningiomas with respect to PR and Ki67 status. Spearman correlation showed a clearly significant inverse relationship between the two antibodies. Conclusion: The use of immunohistochemical markers aids in determining the aggressive nature of the tumor, its recurrence potential and can be used as prognostic markers.References
1. Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black PM. Epidemiology of intracranial meningioma. Neurosurgery. 2005 Dec;57(6):1088-1095; discussion 1088-1095.
2. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro-oncology. 2015 Oct;17 Suppl 4:iv1-iv62.
3. Commins DL, Atkinson RD, Burnett ME. Review of meningioma histopathology. Neurosurg Focus. 2007;23(4):E3.
4. Perry A, Brat DJ. Philadelphia: Churchill Livingstone; 2010. Practical Surgical Neuropathology: A diagnostic approach; pp. 185–218.
5. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016 Jun;131(6):803–20.
6. Choi SJ, Chang ED, Kwon SO, Kye DK, Park CK, Lee SW, et al. Comparison of Proliferative Activity in Each Histological Subtypes of Benign and Atypical Intracranial Meningiomas by PCNA and Ki-67 Immunolabeling. Journal of Korean Neurosurgical Society. 2000 Sep 1;29(9):1215–21.
7. Yang S-Y, Park C-K, Park S-H, Kim DG, Chung YS, Jung H-W. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatr. 2008 May;79(5):574–80.
8. Shrestha P, Shrestha I, Kurisu K. Usefulness of Ki-67 in the histological evaluation of neoplastic lesions of central nervous system. Journal of Institute of Medicine. 2008;30(1):68–71.
9. Karabağli P, Sav A. Proliferative indices (MIB-1) in meningiomas: Correlation with the histological subtypes and grades. Journal of Neurological Sciences [Turkish]. 2006; 23(4):279-86.
10. Roser F. The prognostic value of progesterone receptor status in meningiomas. Journal of Clinical Pathology. 2004 Oct 1;57(10):1033–7.
11. Chatterjee U, Mukherjee S, Ghosh S, Chatterjee S. Detection of progesterone receptor and the correlation with Ki-67 labeling index in meningiomas. Neurology India. 2011;59(6):817.
12. Sakr SA, Salem M. Atypical meningioma: Clinicopathological analysis of a new WHO classification. Pan Arab Journal of Neurosurgery. 2011;15(1):36–41.
13. Challa S, Babu S, Uppin S, Uppin M, Panigrahi M, Saradhi V, et al. Meningiomas: Correlation of Ki67 with histological grade. Neurology India. 2011;59(2):204.
14. Intisar s.h. Patty.Central nervous system tumors a clinicopathological study Kurdistan 1st conference on biological sciences j. dohuk Univ., vol. 11, no. 1, 2008.
15. Violaris K, Katsarides V, Sakellariou P. The Recurrence Rate in Meningiomas: Analysis of Tumor Location, Histological Grading, and Extent of Resection. Open Journal of Modern Neurosurgery. 2012;02(01):6–10.
16. Amatya VJ, Takeshima Y, Sugiyama K, Kurisu K, Nishisaka T, Fukuhara T, et al. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas. Hum Pathol. 2001 Sep;32(9):970–5.
17. Shayanfar N, Mashayekh M, Mohammadpour M. Expression of Progestrone Receptor and Proliferative Marker ki 67, in Various Grades of Meningioma. Acta Medica Iranica. 2010;48(3):142–7.
18. Brandis A, Mirzai S, Tatagiba M, Walter GF, Samii M, Ostertag H. Immunohistochemical detection of female sex hormone receptors in meningiomas: correlation with clinical and histological features. Neurosurgery. 1993 Aug;33(2):212-217; discussion 217-218.
19. Wolfsberger S, Doostkam S, Boecher-Schwarz H-G, Roessler K, van Trotsenburg M, Hainfellner JA, et al. Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature. Neurosurg Rev. 2004 Oct;27(4):238–45.
2. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro-oncology. 2015 Oct;17 Suppl 4:iv1-iv62.
3. Commins DL, Atkinson RD, Burnett ME. Review of meningioma histopathology. Neurosurg Focus. 2007;23(4):E3.
4. Perry A, Brat DJ. Philadelphia: Churchill Livingstone; 2010. Practical Surgical Neuropathology: A diagnostic approach; pp. 185–218.
5. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016 Jun;131(6):803–20.
6. Choi SJ, Chang ED, Kwon SO, Kye DK, Park CK, Lee SW, et al. Comparison of Proliferative Activity in Each Histological Subtypes of Benign and Atypical Intracranial Meningiomas by PCNA and Ki-67 Immunolabeling. Journal of Korean Neurosurgical Society. 2000 Sep 1;29(9):1215–21.
7. Yang S-Y, Park C-K, Park S-H, Kim DG, Chung YS, Jung H-W. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatr. 2008 May;79(5):574–80.
8. Shrestha P, Shrestha I, Kurisu K. Usefulness of Ki-67 in the histological evaluation of neoplastic lesions of central nervous system. Journal of Institute of Medicine. 2008;30(1):68–71.
9. Karabağli P, Sav A. Proliferative indices (MIB-1) in meningiomas: Correlation with the histological subtypes and grades. Journal of Neurological Sciences [Turkish]. 2006; 23(4):279-86.
10. Roser F. The prognostic value of progesterone receptor status in meningiomas. Journal of Clinical Pathology. 2004 Oct 1;57(10):1033–7.
11. Chatterjee U, Mukherjee S, Ghosh S, Chatterjee S. Detection of progesterone receptor and the correlation with Ki-67 labeling index in meningiomas. Neurology India. 2011;59(6):817.
12. Sakr SA, Salem M. Atypical meningioma: Clinicopathological analysis of a new WHO classification. Pan Arab Journal of Neurosurgery. 2011;15(1):36–41.
13. Challa S, Babu S, Uppin S, Uppin M, Panigrahi M, Saradhi V, et al. Meningiomas: Correlation of Ki67 with histological grade. Neurology India. 2011;59(2):204.
14. Intisar s.h. Patty.Central nervous system tumors a clinicopathological study Kurdistan 1st conference on biological sciences j. dohuk Univ., vol. 11, no. 1, 2008.
15. Violaris K, Katsarides V, Sakellariou P. The Recurrence Rate in Meningiomas: Analysis of Tumor Location, Histological Grading, and Extent of Resection. Open Journal of Modern Neurosurgery. 2012;02(01):6–10.
16. Amatya VJ, Takeshima Y, Sugiyama K, Kurisu K, Nishisaka T, Fukuhara T, et al. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas. Hum Pathol. 2001 Sep;32(9):970–5.
17. Shayanfar N, Mashayekh M, Mohammadpour M. Expression of Progestrone Receptor and Proliferative Marker ki 67, in Various Grades of Meningioma. Acta Medica Iranica. 2010;48(3):142–7.
18. Brandis A, Mirzai S, Tatagiba M, Walter GF, Samii M, Ostertag H. Immunohistochemical detection of female sex hormone receptors in meningiomas: correlation with clinical and histological features. Neurosurgery. 1993 Aug;33(2):212-217; discussion 217-218.
19. Wolfsberger S, Doostkam S, Boecher-Schwarz H-G, Roessler K, van Trotsenburg M, Hainfellner JA, et al. Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature. Neurosurg Rev. 2004 Oct;27(4):238–45.
Published
2017-12-19
Issue
Section
Original Article
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
